BlossomHill Therapeutics raises a $100M series B to work on precision medicine small molecules

blonca9
Mar 1, 2024
1 min read

Scientific founder, president & CEO J. Jean Cui describes her scientific approach of working to solve resistance mutations, and she previews three of BlossomHill's programs.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

BlossomHill Therapeutics raises a $100M series B to work on precision medicine small molecules

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight